NCT03727724View on ClinicalTrials.gov

Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

December 4, 2018

Primary Completion Date

September 6, 2022

Study Completion Date

September 6, 2022

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

Afatinib

Tablet

DRUG

Cetuximab

Injection

Trial Locations (4)

1066 CX

Antoni van Leeuwenhoek, Amsterdam

1007 MB

VU Medical Center, Amsterdam

9713 GZ

University Medical Center Groningen, Groningen

6229 HX

Maastricht UMC+, Maastricht

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

collaborator

Merck Serono International SA

INDUSTRY

lead

The Netherlands Cancer Institute

OTHER

NCT03727724 - Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer | Biotech Hunter | Biotech Hunter